220 related articles for article (PubMed ID: 21285676)
1. C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy.
Yu EY; Muzi M; Hackenbracht JA; Rezvani BB; Link JM; Montgomery RB; Higano CS; Eary JF; Mankoff DA
Clin Nucl Med; 2011 Mar; 36(3):192-8. PubMed ID: 21285676
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.
Fricke E; Machtens S; Hofmann M; van den Hoff J; Bergh S; Brunkhorst T; Meyer GJ; Karstens JH; Knapp WH; Boerner AR
Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):607-11. PubMed ID: 12589476
[TBL] [Abstract][Full Text] [Related]
4. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
[TBL] [Abstract][Full Text] [Related]
5. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy?
Pietrzak AK; Czepczynski R; Wierzchoslawska E; Cholewinski W
Urol J; 2018 Sep; 15(5):242-247. PubMed ID: 29681049
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[
Sonni I; Minamimoto R; Baratto L; Gambhir SS; Loening AM; Vasanawala SS; Iagaru A
Mol Imaging Biol; 2020 Apr; 22(2):397-406. PubMed ID: 31236756
[TBL] [Abstract][Full Text] [Related]
7. 11C-acetate PET imaging of prostate cancer.
Oyama N; Akino H; Kanamaru H; Suzuki Y; Muramoto S; Yonekura Y; Sadato N; Yamamoto K; Okada K
J Nucl Med; 2002 Feb; 43(2):181-6. PubMed ID: 11850482
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
9. Is (99m)Tc-MDP whole body bone scintigraphy adjuvant to (18)F-FDG-PET for the detection of skeletal metastases?
Sahin E; Zincirkeser S; Akcan AB; Elboga U
J BUON; 2014; 19(1):291-6. PubMed ID: 24659678
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
11. Comparison of (18)F-FDG-PET/CT with (99m)Tc-MDP bone scintigraphy for the detection of bone metastases in cancer patients.
Ozülker T; Küçüköz Uzun A; Ozülker F; Ozpaçac T
Nucl Med Commun; 2010 Jun; 31(6):597-603. PubMed ID: 20224457
[TBL] [Abstract][Full Text] [Related]
12. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
Ak I; Sivrikoz MC; Entok E; Vardareli E
Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
[TBL] [Abstract][Full Text] [Related]
13. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival.
Vargas HA; Wassberg C; Fox JJ; Wibmer A; Goldman DA; Kuk D; Gonen M; Larson SM; Morris MJ; Scher HI; Hricak H
Radiology; 2014 Apr; 271(1):220-9. PubMed ID: 24475817
[TBL] [Abstract][Full Text] [Related]
14. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
15. Comparison of diagnostic ability between (99m)Tc-MDP bone scan and (18)F-FDG PET/CT for bone metastasis in patients with small cell lung cancer.
Lee JW; Lee SM; Lee HS; Kim YH; Bae WK
Ann Nucl Med; 2012 Oct; 26(8):627-33. PubMed ID: 22729551
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer.
Ito S; Kato K; Ikeda M; Iwano S; Makino N; Tadokoro M; Abe S; Nakano S; Nishino M; Ishigaki T; Naganawa S
J Nucl Med; 2007 Jun; 48(6):889-95. PubMed ID: 17504877
[TBL] [Abstract][Full Text] [Related]
17. Detection of Bone Metastases Using 11C-Acetate PET in Patients with Prostate Cancer with Biochemical Recurrence.
Spick C; Polanec SH; Mitterhauser M; Wadsak W; Anner P; Reiterits B; Haug AR; Hacker M; Beheshti M; Karanikas G
Anticancer Res; 2015 Dec; 35(12):6787-91. PubMed ID: 26637897
[TBL] [Abstract][Full Text] [Related]
18. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.
Nuñez R; Macapinlac HA; Yeung HW; Akhurst T; Cai S; Osman I; Gonen M; Riedel E; Scher HI; Larson SM
J Nucl Med; 2002 Jan; 43(1):46-55. PubMed ID: 11801702
[TBL] [Abstract][Full Text] [Related]
19. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases.
Kao CH; Hsieh JF; Tsai SC; Ho YJ; Yen RF
Anticancer Res; 2000; 20(3B):2189-92. PubMed ID: 10928175
[TBL] [Abstract][Full Text] [Related]
20. Comparison of bone scintigraphy and 18F-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases.
Ozcan Kara P; Kara T; Kara Gedik G; Sari O; Sahin O
Rev Esp Med Nucl; 2011; 30(2):94-6. PubMed ID: 21342722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
